Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- HF pharmacotherapy in midst of paradigm shift
-
- Electrophysiology training in crisis Peter R. Kowey, MD, FACC, FAHA, FHRS; Douglas Esberg, MD, FACC, FHRS; Victoria M. Robinson, MBChB, MRCP
- Andrea M. Russo, MD, emphasizes importance of learning, collaboration
- Weight loss recommended to decrease CV risk in metabolically healthy obesity
- FDA approves canagliflozin to treat diabetic kidney disease, heart failure hospitalization
- New trials elevate focus on polypill strategy for CVD prevention
- Children exposed to secondhand smoke at home at greater risk for AF
- Fluoroquinolones pose risk for aortic, mitral regurgitation
- Sleep duration may be predictive of cardiometabolic risk factors, cerebrovascular disease mortality
-
- HiSTORIC: Troponin I-based risk stratification safely identifies low-risk patients
- Next Gen Innovators expound on highlights from TCT
- Rivaroxaban monotherapy noninferior to combo therapy for AF, stable CAD
- Salt substitute reduced hypertension incidence by 55% in Peru
- SCOPE I: Acurate neo does not meet noninferiority for TAVR safety, efficacy vs. Sapien 3
- Subclinical leaflet thrombosis not tied to serious clinical events: PARTNER 3 CT substudy
- Twice-yearly inclisiran injection shows durable LDL improvement: ORION-11
- TWILIGHT: Switching to ticagrelor monotherapy 3 months post-PCI lowers bleeding vs. DAPT
-
- CV controversy of ADHD medication use in children and adolescents Katie Liveoak, PharmD, BCPP; Myaa Lightfoot, PharmD; Sarah Mehringer, PharmD, BCPS, BCCP; Jonathan Bain, PharmD, BCCCP, BCPS (AQ Cardiology); Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
- ATTEST
- EARNEST-PVI
- GALACTIC
- HELP-AF
- IDEAL-LM
- Look AHEAD
- SCOPE I
-
- TWILIGHT